Search
for

    Glossary Vemurafenib

    medication treats melanoma with BRAF gene mutation

    Vemurafenib is a medication used to treat certain types of cancer, specifically melanoma with a mutation in the BRAF gene. It works by inhibiting the activity of the mutated BRAF protein, which helps slow down or stop the growth of cancer cells.

    Research 10 of 117

    1. RASopathic Skin Eruptions during Vemurafenib Therapy PLoS ONE · 2013 · 82 citations
    2. RASopathic alopecia: Hair changes associated with vemurafenib therapy Journal of The American Academy of Dermatology · 2015 · 21 citations
    3. Vemurafenib-induced pityriasis amiantacea: a case report Cutaneous and ocular toxicology · 2015 · 9 citations
    4. Correction: RASopathic Skin Eruptions during Vemurafenib Therapy PLoS ONE · 2013 · 4 citations
    5. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma 2016 · 32 citations
    6. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients. Journal of the European Academy of Dermatology and Venereology · 2014 · 31 citations
    7. Cutaneous toxicities of new treatments for melanoma Clinical & Translational Oncology · 2018 · 25 citations
    8. The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma Current Dermatology Reports · 2013 · 6 citations
    9. Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects PLOS ONE · 2021 · 3 citations
    10. 554 Repurposing a clinical antimalarial for the therapeutic induction of lethal ER stress targeting BRAF-kinase inhibitor-resistant malignant melanoma Journal of Investigative Dermatology · 2016
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →